Last reviewed · How we verify
PACAP38
At a glance
| Generic name | PACAP38 |
|---|---|
| Also known as | Pituitary adenylate cyclase activating polypeptide-38, Pituitary Adenylate Cyclase Activating Peptide 38 |
| Sponsor | Danish Headache Center |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- The Effect of Interventional Procedures on Serum CGRP and PACAP-38 Levels in Chronic Migraine (NA)
- Induction of Migraine Attacks With Aura Using Pituitary Adenylate Cyclase Activating Polypeptide-38 (NA)
- Platelet Rich Plasma Combined With Platelet Rich Fibrin in Management of Temporomandibular Joint Osteoarthritis (NA)
- Comparison of the Effects of Single Versus Triple Injections of Platelet-Rich Plasma in Patients With Knee Osteoarthritis (NA)
- Repeat Dosing of Psilocybin in Migraine Headache (PHASE1)
- Migraine Induction Properties of PACAP-38 After Eptinezumab in Migraine Without Aura Patients. (NA)
- Hypersensitivity to PACAP-38 in Post-Traumatic Headache (NA)
- Short Term Results of Platelet-rich Plasma in the Treatment of Chronic Anal Fissure (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PACAP38 CI brief — competitive landscape report
- PACAP38 updates RSS · CI watch RSS
- Danish Headache Center portfolio CI